J. Michot

B. Besse, O. Lambotte, C. Chouaid, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.

C. Robert, S. Ederhy, B. Besse, 2021, European journal of cancer.

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

E. Vicaut, M. Dougados, M. Humbert, 2021, The Lancet Respiratory Medicine.

Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy

X. Mariette, O. Lambotte, S. Aspeslagh, 2017, Annals of the rheumatic diseases.

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

J. Honnorat, O. Lambotte, F. Bourdain, 2019, Journal of Immunotherapy for Cancer.

Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia

S. de Botton, O. Lambotte, V. Picard, 2015, American journal of hematology.

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience.

J. Soria, J. Armand, V. Ribrag, 2018, European journal of cancer.

Infectious complications in patients treated with immune checkpoint inhibitors.

E. Lanoy, O. Lambotte, J. Michot, 2020, European journal of cancer.

Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.

C. Robert, J. Rossignol, V. Ribrag, 2019, Immunotherapy.

Reply to: "Mortality due to immunotherapy related hepatitis".

D. Samuel, C. Robert, O. Lambotte, 2018, Journal of hepatology.

Repeated courses of low‐dose 2 × 2 Gy radiation therapy in patients with indolent B‐cell non‐Hodgkin lymphomas

A. Schernberg, J. Rossignol, V. Ribrag, 2020, Cancer medicine.

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

J. Soria, S. de Botton, V. Ribrag, 2014, Anti-cancer drugs.

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.

J. Soria, J. Armand, V. Ribrag, 2018, European journal of cancer.

Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication

F. Carbonnel, O. Lambotte, C. Mateus, 2017, Journal of immunotherapy.

A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience

J. Bourhis, S. Koscielny, V. Ribrag, 2018, Leukemia & lymphoma.

[Role of radiotherapy in the treatment of NK/T-cell nasal type and primary cerebral lymphomas].

K. Hoang-Xuan, J. Michot, R. Mazeron, 2016, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.

O. Lambotte, S. Champiat, A. Marabelle, 2021, European journal of cancer.

Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency.

O. Lambotte, N. Anguel, X. Monnet, 2013, QJM : monthly journal of the Association of Physicians.

Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease

O. Lambotte, C. Goujard, J. Delfraissy, 2015, Transfusion.

J. Soria, J. Armand, C. Robert, 2016, European journal of cancer.

Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.

O. Lambotte, N. Penel, M. Kostine, 2021, European journal of cancer.

Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review

C. Lebbé, O. Lambotte, J. Michot, 2020, British journal of haematology.

Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors.

O. Lambotte, C. Mateus, S. Champiat, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

O. Lambotte, C. Mateus, S. Champiat, 2017, European journal of cancer.

Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma

J. Byrd, H. Tilly, A. Chanan-Khan, 2021, Blood.

Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?

T. Phillips, V. Ribrag, J. Michot, 2020, Clinical lymphoma, myeloma & leukemia.

Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.

M. Suarez‐Almazor, X. Mariette, C. Robert, 2021, European journal of cancer.

D. Planchard, E. Deutsch, B. Besse, 2022, Frontiers in Immunology.

Severe COVID-19 in patients with hematological cancers presenting with viremia

P. Cournède, S. Foulon, F. Barlesi, 2021, Annals of Oncology.

Two cases of immune thrombocytopenia associated with pembrolizumab.

C. Robert, O. Lambotte, C. Mateus, 2016, European journal of cancer.

O. Lambotte, V. Ribrag, G. Quéré, 2017, European journal of cancer.

A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)

J. Winter, J. Leonard, Zangdong He, 2016 .

Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score

D. Planchard, B. Besse, L. Mezquita, 2022, Cancers.

Efficacy of Recombinant Human Interleukin 7 in a Patient With Severe Lymphopenia-Related Progressive Multifocal Leukoencephalopathy

J. Bourhis, O. Lambotte, B. Stankoff, 2014, Open forum infectious diseases.

Long-term impact of immunotherapy on quality of life of surviving patients: A multi-dimensional descriptive clinical study.

O. Lambotte, J. Michot, N. Noel, 2021, European journal of cancer.

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

F. Prósper, S. Fudio, A. Oriol, 2016, Cancer medicine.

Kinetic Profiles and Management of Hepatitis B Virus Reactivation in Patients With Immune‐Mediated Inflammatory Diseases

D. Thabut, F. Berenbaum, S. Pol, 2013, Arthritis care & research.

Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?"

D. Samuel, C. Robert, O. Lambotte, 2018, Journal of hepatology.

Real-world data on antiviral treatments for hepatitis C virus infections: Can we deﬁne intention to treat or per protocol analyses?

D. Samuel, C. Robert, O. Lambotte, 2018 .

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

G. Salles, R. Bouabdallah, A. Chanan-Khan, 2019, Blood.

A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia

F. Roudot-thoraval, P. Bierling, J. Viallard, 2013, Haematologica.

Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.

É. Oksenhendler, S. Chevret, V. Meignin, 2012, Blood.

Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.

J. Soria, B. Besse, O. Lambotte, 2020, European journal of cancer.

Renal involvement of lymphomas proven by kidney biopsy: report of 10 cases from a tertiary care center and comparison with the literature

X. Mariette, O. Lambotte, F. Besson, 2022, International Journal of Hematology.

Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.

V. Meignin, J. Emile, L. Arnaud, 2014, Blood.

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

J. Machiels, K. Korski, G. Meneses‐Lorente, 2020, Journal for ImmunoTherapy of Cancer.

Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review

F. Scotté, J. Spano, J. Michot, 2021, Annals of Oncology.

(18)F-FDG PET and CT-scan Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-PD1 Immune Checkpoint Inhibitor

Lawrence H. Schwartz, Roch Houot, Laurent Dercle, 2018 .

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

M. Kersten, M. Hallek, S. Fernandes, 2016, Blood.

Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.

V. Ribrag, S. Aspeslagh, A. Marabelle, 2017, European journal of cancer.

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.

D. Samuel, C. Robert, O. Lambotte, 2018, Journal of hepatology.

Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors

V. Ribrag, J. Michot, 2021, The Lancet.

Adult Burkitt Leukemia/Lymphoma

V. Ribrag, J. Michot, V. Camara-clayette, 2020 .

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

J. Winter, J. Leonard, Juanita Lopez, 2019, Clinical Cancer Research.

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

T. Owa, C. Lucchesi, J. Coindre, 2018, The Lancet. Oncology.

A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features

T. Molina, F. Jardin, G. Salles, 2020, Clinical Cancer Research.

Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

L. Zitvogel, G. Kroemer, E. Solary, 2021, Cell Death & Disease.

Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

F. Jardin, A. Stamatoullas, V. Ribrag, 2021, Human vaccines & immunotherapeutics.

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

N. Chaput, J. Soria, C. Robert, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.

Eric Deutsch, Laurent Dercle, Renaud Mazeron, 2016, European journal of cancer.

Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients

A. Italiano, J. Soria, A. Mcdonald, 2015 .

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

J. Soria, J. Armand, E. Castañón, 2017, European journal of cancer.

Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors

D. Samuel, C. Guettier, O. Rosmorduc, 2020, JHEP reports : innovation in hepatology.

Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.

M. Ducreux, J. Soria, V. Boige, 2020, European journal of cancer.

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

J. Soria, C. Ferté, E. Castañón, 2020, Cancer medicine.

Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.

M. Labetoulle, O. Lambotte, E. Barreau, 2019, American journal of ophthalmology.

Severe chronic primary neutropenia in adults: report on a series of 108 patients.

É. Oksenhendler, P. Moreau, C. Bellanné-Chantelot, 2015, Blood.

Repurposing of anticancer drugs expands possibilities for antiviral and anti-inflammatory discovery in COVID-19.

A. Ribas, J. Soria, J. Michot, 2021, Cancer discovery.

PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)

M. Shipp, P. Zinzani, G. Martinelli, 2014 .

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

N. Chaput, C. Balleyguier, F. Barlesi, 2020, Annals of Oncology.

C. Lebbé, O. Lambotte, S. Ammari, 2022, European journal of cancer.

P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade.

J. Soria, C. Robert, F. Carbonnel, 2017, Journal of Crohn's & colitis.

In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas

T. Molina, F. Berger, F. Carrat, 2016, PloS one.

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

T. Molina, F. Berger, F. Carrat, 2015, American journal of hematology.

CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy

L. Zitvogel, J. Adam, V. Ribrag, 2021, Cancers.

Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group

M. Dougados, M. Humbert, G. Baron, 2022, eClinicalMedicine.

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

E. Vicaut, M. Dougados, M. Humbert, 2021, The Lancet Rheumatology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study".

D. Samuel, C. Robert, O. Lambotte, 2018, Journal of hepatology.

Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study.

J. Blay, J. Baselga, J. Tabernero, 2018, JCO precision oncology.

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma

J. Bosq, J. Rossignol, V. Ribrag, 2021, Cancer drug resistance.

How to manage patients with corticosteroids in oncology in the era of immunotherapy?

F. Scotté, O. Lambotte, A. Marabelle, 2020, European journal of cancer.

Updates in the Treatment of Peripheral T-Cell Lymphomas

V. Ribrag, J. Michot, K. Saleh, 2021, Journal of experimental pharmacology.

Exploring the genetic landscape of HCV-related B-cell lymphomas using whole exome sequencing

V. Meignin, F. Davi, B. Tesson, 2023, Leukemia.

Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors

D. Samuel, C. Robert, O. Lambotte, 2018 .

Ibrutinib-Induced Neutrophilic Dermatosis

D. Ghez, J. Michot, L. El Halabi, 2017, The American Journal of dermatopathology.

Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors

F. Ducray, Marion Benazra, D. Leclercq, 2021, Neurology: Neuroimmunology & Neuroinflammation.

Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy.

O. Lambotte, C. Cauquil, J. Michot, 2021, European journal of cancer.

Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae

A. Echaniz-Laguna, O. Lambotte, A. Masseau, 2021, Brain communications.

The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study.

P. Chanson, X. Mariette, J. Soria, 2020, European journal of cancer.

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

A. Italiano, I. Braña, I. Aronchik, 2023, Nature Communications.

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.

N. Chaput, J. Soria, C. Robert, 2017 .

Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

T. Molina, O. Casasnovas, P. Feugier, 2022, Blood advances.

New insights on IgA vasculitis with underlying solid tumor: a nationwide French study of 30 patients

C. Combe, Z. Amoura, A. Aouba, 2020, Clinical Rheumatology.

THU0628 IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY)

M. Suarez‐Almazor, X. Mariette, J. Gottenberg, 2019, Poster Presentations.

Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.

S. Koscielny, J. Bosq, S. de Botton, 2015, European journal of cancer.

Large granular lymphocyte leukemia and lymphomatoid granulomatosis in the same patient: fortuitous association?

O. Lambotte, M. Raphael, C. Goujard, 2013, Leukemia & lymphoma.

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

J. Soria, C. Rolfo, A. Awada, 2017, Clinical Cancer Research.

High‐dose cyclophosphamide for hard‐to‐treat patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma, a phase II result

J. Rossignol, V. Ribrag, C. Willekens, 2019, European journal of haematology.

Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L‐asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T‐cell lymphoma: A French retrospective study

P. Gaulard, G. Salles, L. Fornecker, 2023, British journal of haematology.

Severe gastro-intestinal angiodysplasia in context of Heyde's syndrome durably cured after aortic valve replacement.

Y. Bouhnik, J. Fabiani, C. Brink, 2012, Presse medicale.

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

P. Tiberghien, F. Barlesi, F. Griscelli, 2021, Annals of Oncology.

Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.

Qun Zhang, T. Lv, Yong Song, 2017, Translational lung cancer research.

Local treatment for scleritis secondary to Wiskott-Aldrich syndrome.

M. Labetoulle, O. Lambotte, A. Rousseau, 2016, Journal francais d'ophtalmologie.

Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

N. Chaput, F. André, J. Soria, 2020, Nature Cancer.

Very prolonged liposomal amphotericin B use leading to a lysosomal storage disease.

O. Lambotte, O. Lortholary, S. Blanche, 2014, International journal of antimicrobial agents.

Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study

O. Bernard, V. Ribrag, C. Quivoron, 2023, Cancers.

Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report

N. Chaput, C. Balleyguier, F. Barlesi, 2020 .

Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma

A. Aupérin, V. Ribrag, C. Massard, 2022, Haematologica.

PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment

M. Shipp, P. Zinzani, P. Armand, 2015 .

Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study

O. Bernard, J. Soria, L. Lacroix, 2023, American journal of hematology.

Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.

J. Rossignol, V. Ribrag, V. Vergé, 2020, Clinical lymphoma, myeloma & leukemia.

Mortalité du syndrome d’activation macrophagique de l’adulte en 2013

J. Michot, C. Rivoisy, F. Ackermann, 2013 .

Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin’s lymphoma not eligible for intensive chemotherapy

J. Rossignol, V. Ribrag, C. Willekens, 2021, European journal of haematology.

Burkitt and Burkitt-Like Lymphomas: a Systematic Review

V. Ribrag, J. Michot, V. Camara-clayette, 2020, Current Oncology Reports.

PALLIA 10 score in phase I cancer studies

J. Soria, F. Scotté, V. Ribrag, 2022, BMJ supportive & palliative care.

Adenosine deaminase is a useful biomarker to diagnose pleural tuberculosis in low to medium prevalence settings.

O. Lambotte, Y. Madec, S. Bulifon, 2016, Diagnostic microbiology and infectious disease.

Multiple immune-related toxicities in cancer patients treated with anti-programmed death 1 immunotherapies: a new surrogate marker for clinical trials?

C. Robert, B. Besse, O. Lambotte, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon

F. Carbonnel, C. Massard, J. Michot, 2021, EXCLI journal.

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

P. Riedell, H. Tilly, Jitendra Kanodia, 2022, Blood.

Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study.

C. Balleyguier, C. Robert, B. Besse, 2021, European journal of cancer.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

E. Solary, O. Mir, T. de Baère, 2018, European journal of cancer.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers

E. Solary, T. de Baère, S. Michiels, 2018, Oncotarget.

Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

J. Blay, J. Baselga, J. Tabernero, 2015 .

Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.

J. Soria, C. Robert, B. Besse, 2022, Cancer treatment reviews.

Identification of new prognostic factors in phase I patients treated by immunotherapy

J. Soria, J. Armand, V. Ribrag, 2016 .

Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study

M. Shipp, P. Zinzani, P. Armand, 2016 .

Profile and outcome of cancer patients enrolled in contemporary phase I trials.

Y. Loriot, V. Ribrag, S. Ammari, 2023, European Journal of Cancer.

Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic

S. Michiels, J. Soria, F. Barlesi, 2021, Cancer Cell.

Late Recurrent Testicular Seminoma: Histological Evidence Is Required

M. Gizzi, O. Lambotte, C. Lebacle, 2015, Oncology Research and Treatment.

Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy.

O. Lambotte, S. Champiat, A. Marabelle, 2017, European journal of cancer.

Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?"

D. Samuel, C. Robert, O. Lambotte, 2019, Journal of Hepatology.

Prevalence and clinical patterns of ocular complications associated with anti PD‐1/PDL‐1 anticancer immunotherapy

Š., M., A. Best, 2018, Acta Ophthalmologica.

Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B‐cell lymphoma, a clinico‐pathological series of 25 cases

C. Copie-Bergman, T. Molina, G. Salles, 2020, British journal of haematology.

THU0649 PHENOTYPIC CLUSTERS OF RHEUMATIC/SYSTEMIC IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES (IMMUNOCANCER INTERNATIONAL REGISTRY)

M. Suarez‐Almazor, X. Mariette, J. Gottenberg, 2019, Poster Presentations.

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

S. Ferrari, S. Carrancio, J. Kuruvilla, 2021, Blood.

A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma

M. Kersten, R. Bouabdallah, P. Zinzani, 2016 .

MA05.11 Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural Mesothelioma

D. Planchard, X. Paoletti, J. Soria, 2019, Journal of Thoracic Oncology.

Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110.

P. Pauwels, C. Rolfo, A. Awada, 2016 .

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

X. Paoletti, J. Soria, J. Armand, 2018, British Journal of Cancer.

Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

X. Paoletti, V. Ribrag, A. Hollebecque, 2019 .

10PSafety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

X. Paoletti, V. Ribrag, A. Hollebecque, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Psychosis, paraplegia and coma revealing methylenetetrahydrofolate reductase deficiency in a 56-year-old woman

F. Sedel, T. Papo, J. Michot, 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

Belantamab Mafotodin-Induced Epithelial Keratopathy Masquerading Myopic Surgery.

M. Labetoulle, A. Rousseau, J. Michot, 2020, Ophthalmology.

Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases.

V. Ribrag, D. Ghez, J. Michot, 2023, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[Disseminated varicella-zoster virus infection with hemorrhagic gastritis during the course of chronic lymphocytic leukemia: case report and literature review].

F. Carbonnel, O. Lambotte, J. Michot, 2014, La Revue de medecine interne.

PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL

R. Clynes, J. Michot, K. Patel, 2022, HemaSphere.

EZH2 GAIN‐OF‐FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS

J. Vose, J. Fitzgibbon, N. Nagy, 2019, Hematological Oncology.

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series

E. Assenat, O. Dereure, K. Klouche, 2023, Journal for ImmunoTherapy of Cancer.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)

F. Morschhauser, S. Carrancio, J. Chavez, 2023, Hematological Oncology.

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

M. Shipp, P. Zinzani, P. Armand, 2016 .

Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.

É. Oksenhendler, S. Chevret, V. Meignin, 2012, Blood.

Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study

O. Bernard, J. Soria, L. Lacroix, 2023, American journal of hematology.

Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.

J. Rossignol, V. Ribrag, V. Vergé, 2020, Clinical lymphoma, myeloma & leukemia.

18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti–Programmed Death 1 Immune Checkpoint Inhibitor

R. Houot, L. Schwartz, L. Dercle, 2018, The Journal of Nuclear Medicine.

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

J. Soria, J. Armand, E. Castañón, 2017, European journal of cancer.

Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.

B. Besse, O. Lambotte, S. Ammari, 2022, Respiratory medical research.

Tolerability of immune checkpoint inhibitors in patients with cancer and pre-existing multiple sclerosis.

C. Cauquil, J. Michot, L. Chavaz, 2023, European journal of cancer.